Literature DB >> 11747988

Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase.

Li Liu1, Tashandra Underwood, Han Li, Rifat Pamukcu, W Joseph Thompson.   

Abstract

The structure of cyclic GMP (cGMP)-binding (cGB), cGMP specific phosphodiesterase (PDE5) comprises several domains. We have used RT-PCR methods to clone the noncatalytic cGB domains of PDE5 from human colon cancer cell RNA and constructed glutathione-S-transferase (GST) fusion proteins to express and study the domains. One fragment showed 94% identity to bovine PDE5 and coded for the high affinity cGB domain of PDE5 (Val(156)-Asp(394), cGB-I). Another cloned fragment showed 92% identity to bovine PDE5 and coded for the phosphorylation site plus both high and low affinity cGB domains of PDE5 (Val(36)-Glu(529), cGB-II). Both fragments expressed as GST-cGB fusion proteins bound cGMP specifically, as determined by competitive [3H]-cGMP ligand binding. We found that cGB-I showed high affinity cGMP binding with K(d)=0.33 microM. cGB-II showed two cGMP binding sites with similar affinities and specificity to the native enzyme. cGB-II was phosphorylated by cGMP-dependent protein kinase (PKG) as reported for bovine PDE5. These data show that recombinant regulatory regions of PDE5 form cGB sites similar to native enzyme sites and confirm proposed domain functions. These results establish that recombinant fusion proteins of PDE5 domains may be used to further characterize the structure of PDE5.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11747988     DOI: 10.1016/s0898-6568(01)00216-9

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  10 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

Authors:  Anindita Das; David Durrant; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2014-10-31       Impact factor: 12.310

3.  Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of ligand binding and dimerization.

Authors:  Sergio E Martinez; Sandra Bruder; Anita Schultz; Ning Zheng; Joachim E Schultz; Joseph A Beavo; Jürgen U Linder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-11       Impact factor: 11.205

4.  The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding.

Authors:  Sergio E Martinez; Albert Y Wu; Natalie A Glavas; Xiao-Bo Tang; Stewart Turley; Wim G J Hol; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

Review 5.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

6.  Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain.

Authors:  Huanchen Wang; Howard Robinson; Hengming Ke
Journal:  J Biol Chem       Date:  2010-09-21       Impact factor: 5.157

7.  Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin.

Authors:  Kevin J Lee; Wen-Chi L Chang; Xi Chen; Jacob Valiyaveettil; Veronica Ramirez-Alcantara; Elaine Gavin; Alla Musiyenko; Luciana Madeira da Silva; Naga S Annamdevula; Silas J Leavesley; Antonio Ward; Tyler Mattox; Ashley S Lindsey; Joel Andrews; Bing Zhu; Charles Wood; Ashleigh Neese; Ashley Nguyen; Kristy Berry; Yulia Maxuitenko; Mary Pat Moyer; Elmar Nurmemmedov; Greg Gorman; Lori Coward; Gang Zhou; Adam B Keeton; Harry S Cooper; Margie L Clapper; Gary A Piazza
Journal:  Cancer Prev Res (Phila)       Date:  2021-09-28

8.  Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling.

Authors:  Florian Mullershausen; Andreas Friebe; Robert Feil; W Joseph Thompson; Franz Hofmann; Doris Koesling
Journal:  J Cell Biol       Date:  2003-02-25       Impact factor: 10.539

9.  Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme.

Authors:  F Mullershausen; M Russwurm; W J Thompson; L Liu; D Koesling; A Friebe
Journal:  J Cell Biol       Date:  2001-10-15       Impact factor: 10.539

10.  Role of phosphodiesterase 5 in synaptic plasticity and memory.

Authors:  Daniela Puzzo; Salvatore Sapienza; Ottavio Arancio; Agostino Palmeri
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.